Quantifying the Contribution of Lipoprotein(a) to All apoB-Containing Particles

Every atherogenic particle — LDL and lipoprotein(a) alike — carries one apoB. This large analysis asked a precise question: how much of a person’s total atherogenic-particle burden is actually Lp(a)?

Across more than 158,000 individuals, Lp(a) accounted for a median of only about 3 percent of all apoB-containing particles — small, on average. But the average hides the people who matter most. In those with the highest Lp(a) levels, the contribution rose to 15 percent and, in some individuals, up to 40 percent. And in patients whose LDL was well controlled but whose Lp(a) was high, Lp(a) became a dominant share of the remaining atherogenic burden.

The insight explains a clinical puzzle: why some patients keep having events despite a “good” LDL. For them, Lp(a) is the hidden driver of residual risk, and a standard cholesterol panel will not reveal it.

We rate the evidence strong. It is a very large, methodologically clean analysis that quantifies, in concrete particle terms, when Lp(a) goes from a minor contributor to the main event — reinforcing the case for measuring it, especially in patients with controlled LDL but persistent risk.